TransCode Therapeutics
RNAZ
6 hedge funds and large institutions have $26.4K invested in TransCode Therapeutics in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
1.31% less ownership
Funds ownership: 1.73% → 0.42% (-1.3%)
25% less funds holding
Funds holding: 8 → 6 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
83% less capital invested
Capital invested by funds: $155K → $26.4K (-$129K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$30.4K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$126K |
| 2 |
Citigroup
New York
|
-$17K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$10.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $20.2K | +$30.4K | +2,964 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $6.06K | +$7.64K | +745 | +525% |
|
|
SS
3
SBI Securities
Tokyo,
Japan
| $68 | – | – | – |
|
4
Bank of America
Charlotte,
North Carolina
| $55 | – | – | – |
|
5
Osaic Holdings
Scottsdale,
Arizona
| $20 | – | – | – |
|
|
DS
6
DRW Securities
Chicago,
Illinois
| – | -$126K | -11,702 | Closed |
|
|
7
Citigroup
New York
| – | -$17K | -1,586 | Closed |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$10.5K | -975 | Closed |
|
RNAZ Hedge Fund Activity: Q4 2025 in Review
6 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q4 2025, worth a combined $26.4K — down 83% from $155K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of RNAZ and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, opening a new position worth an estimated $30.4K. The largest seller was DRW Securities, exiting entirely with an estimated $126K sold.
- 6 institutional investors held TransCode Therapeutics (RNAZ) as of Q4 2025, down from 8 in Q3 2025.
- Funds reported $26.4K of TransCode Therapeutics stock for Q4 2025, down 83% quarter-over-quarter.
- 1 fund opened new TransCode Therapeutics positions in Q4 2025 and 3 closed out, a net change of -2 holders.
- The largest TransCode Therapeutics buyer in Q4 2025 was UBS Group, an estimated $30.4K added.
- The largest TransCode Therapeutics seller in Q4 2025 was DRW Securities, an estimated $126K sold.
Based on aggregated 13F filings for Q4 2025.